Please login to the form below

Not currently logged in
Email:
Password:

Dendreon appoints new R&D lead

Dr Bruce Brown joins the Californian biopharmaceutical group as senior VP

Bruce BrownCancer vaccine company Dendreon has added to its senior team, appointing Dr Bruce Brown as its new senior vice president, medical.

The appointment comes at a time when the Californian biopharma drives to expand the use of Provenge (sipuleucel-T).

Dr Brown’s new role will see him head the company’s R&D organisation, including research and discovery, clinical development and exploring Dendreon’s therapeutic platform for alternative oncology indications.

James Caggiano, chief executive officer, Dendreon, said: “With the addition of Bruce, a board-certified urologist and experienced medical director, to our growing leadership team, we are intensifying our focus on urologists who are uniquely positioned to deliver long-term care to men with prostate cancer.

“Bruce’s valuable background leading major medical organisations makes him the ideal fit to accelerate our R&D programme and oversee our efforts to evaluate the use of Provenge in early-stage prostate cancer, with the hope of curing more men of the disease.”

Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).

He said: “Having launched my medical career as a practicing urologist, I am excited by the prospect of improving the lives of men living with prostate cancer through expanded use of Provenge, both in the US and around the world.

“I look forward to working with Dendreon’s experienced team.”

21st November 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
#DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...